Evidence map›Paper›PMID 37775282›Full record

ArticleBMJ open2023

Goal-directed versus outcome-based financial incentives for smoking cessation among low-income, hospitalised patients: rationale and design of the Financial Incentives for Smoking Treatment II (FIESTA II) randomised controlled trial.

Soma Wali, Anisha Gaitonde, Scott Sherman, Noelle Min, Andrea Pesantes, Ava Bidgoli, Abraelle Shirley, Chi-Hong Tseng, Joseph Ladapo

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03979885 (Financial Incentives for Smoking Treatment), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03979885 naactive not recruitingnot on this map

Financial Incentives for Smoking Treatment

TypeinterventionalSponsorUniversity of California, Los AngelesRan2020 to 2027Enrolled1,058ConditionsSmoking Cessation, Tobacco Use CessationArmsSmoking cessation counseling (Quitline), Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy), Financial incentives for smoking cessation, Financial incentives for use of evidence-based smoking cessation therapies
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Incentives for smoking cessation.The Cochrane database of systematic reviews · 2025
    Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Soma WaliDepartment of Medicine, Olive View-University of California Los Angeles (UCLA) Medical Center, Sylmar, California, USA swali@dhs.lacounty.gov.ORCID 0000-0002-5285-2876
Anisha GaitondeDepartment of Medicine, Olive View-University of California Los Angeles (UCLA) Medical Center, Sylmar, California, USA.
Scott ShermanDepartment of Medicine, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0003-1752-7303
Noelle MinDepartment of Medicine, Burrell College of Osteopathic Medicine, Las Cruces, New Mexico, USA.
Andrea PesantesDepartment of Biology, St John's University, New York, NY, USA.
Ava BidgoliDivision of Research, Department of Internal Medicine, Olive View-University of California Los Angeles (UCLA) Medical Center, Sylmar, California, USA.
Abraelle ShirleyDivision of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Chi-Hong TsengDivision of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Joseph LadapoDivision of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
University of California, Los Angeles · USNew York University · USSt. John's University · US

Funding

Financial incentive strategies for smoking cessation in high-risk, hospitalized patients.R01DA045688 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LADAPO, JOSEPH ABIODUN, SHERMAN, SCOTT E · 2019 to 2023
$3.8M
NIDA NIH HHS R01 DA045688
6 · The paper itself

Abstract

introductionSmoking remains the leading preventable cause of death in the USA. Low utilisation of treatments for smoking cessation remains a major barrier for reducing smoking rates. Financial incentives represent an innovative approach to increasing use of therapies for smoking cessation. This paper will describe the rationale and design of the Financial Incentives for Smoking Treatment II (FIESTA II) study, a randomised controlled trial to evaluate the effectiveness and feasibility of goal-directed and outcome-based financial incentives to promote smoking cessation among hospitalised smokers. METHODS AND ANALYSIS: We are recruiting adult participants who smoked tobacco in the 30 days prior to initial interview and are contemplating quitting smoking. These participants will come from two hospitals in underserved communities in New York City and Los Angeles. They will be randomised into one of three arms. The first arm consists of goal-directed financial incentives plus enhanced usual care, which includes hospital-directed information about quitting smoking, nicotine replacement therapy and referral to a Quitline. The second arm involves outcome-based financial incentives plus enhanced usual care. The third arm consists of enhanced usual care alone. Multiple phone interviews with the participants will be completed after randomisation to assess smoking cessation. Participants will earn $20 for each follow-up interview completed and $30 for each smoking cessation test completed. Those who are randomised to the financial incentive groups can earn an additional $700. The participants in the outcome-based group will receive payments solely for exhibiting cessation, whereas the participants in the goal-based group are also eligible for receiving payments after meeting milestones such as speaking with a helpline coach. ETHICS: Human research protection committees at New York University School of Medicine and the University of California Los Angeles (UCLA) David Geffen School of Medicine granted ethics approval. TRIAL REGISTRATION NUMBER: NCT03979885.

Indexed as

Smoking CessationAdultGoalsHumansMotivationNew York CityRandomized Controlled Trials as TopicSmokingTobacco Use Cessation DevicesCardiologyONCOLOGYPREVENTIVE MEDICINERisk FactorsStroke medicine

Identifiers

PMID37775282
PMCPMC10546144
OpenAlexW4387164711

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.